Approval · Notice of Compliance 25582 · 2021
DUODOPA: Notice of Compliance 25582
Issued April 1, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25582
- Date
- April 1, 2021
- Company
- AbbVie CorporationSaint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Labelling updates including converting the product monograph to the new 2020 pm master template
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| DUODOPA | Not yet assigned | — |
Medicinal ingredients
- LEVODOPA 2 G per 100ML
- CARBIDOPA MONOHYDRATE 0.5 G per 100ML